Verastem, Inc. (VSTM)

Market Cap	74.33M
Revenue (ttm)	n/a
Net Income (ttm)	-105.52M
Shares Out	25.33M
EPS (ttm)	-4.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	390,044
Open	3.190
Previous Close	3.250
Day's Range	2.920 - 3.223
52-Week Range	2.800 - 14.220
Beta	0.27
Analysts	Strong Buy
Price Target	25.69 (+775.3%)
Earnings Date	Aug 6, 2024

About VSTM

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 27, 2012
• Employees: 73
• Stock Exchange: NASDAQ
• Ticker Symbol: VSTM

Analyst Forecast

According to 8 analysts, the average rating for VSTM stock is "Strong Buy." The 12-month stock price forecast is $25.69, which is an increase of 775.30% from the latest price.

Price Target

$25.69

(775.30% upside)

Analyst Consensus: Strong Buy